Severe acute cholestatic hepatitis of unknown etiology successfully treated with the Chinese herbal medicine Inchinko-to (TJ-135)

Susumu Ohwada, Isao Kobayashi, Nobuo Harasawa, Kyoichiro Tsuda, Yosikatsu Inui

INTRODUCTION

Treatment of severe acute hepatitis of unknown etiology is difficult, and the disease often progresses to subacute fulminant hepatitis or late-onset hepatic failure[8]. Several studies have reported on the effectiveness of Inchinko-to, a Chinese herbal medicine used to treat liver disorders and jaundice in Japan[2-5]. Successful treatment of acute hepatic failure of unknown etiology with Inchinko-to has been reported[6].

We treated a patient who suffered from severe acute cholestatic hepatitis of unknown etiology with Inchinko-to. The treatment was effective with no adverse effects. We report and discuss the case.

CASE REPORT

The patient was a 45-year-old man, who had fatigue, vomiting, slight fever, and noticed that his urine had been darker than usual for 1 mo before visiting the clinic. He began to suffer from severe fatigue and loss of appetite, and thus visited the clinic. On physical examination, his skin was dark yellow, without a palpable liver. Liver function tests revealed severe liver dysfunction (Table 1). He was a well-nourished, healthy man with a history of duodenal ulcer. He did not drink alcohol and had no history of blood or blood products transfusion or the use of any drugs, including herbal medicine. He was exposed to no known environmental hazards. His older brother had non-alcoholic steatohepatitis and underwent surgery for rectal carcinoma. Abdominal ultrasonography showed a severely swollen gallbladder and normal intra- and extrahepatic bile ducts; the liver shape and architecture were normal. Upper endoscopy showed an edematous narrowing at the post-bulbar portion of the duodenum and a duodenal ulcer scar in the duodenal bulb.

He was admitted to the hospital. Ursodeoxycholic acid (UDCA) was started at 600 mg daily. Tests for hepatitis A, B, C, and E viruses, Epstein-Barr virus and cytomegalovirus were all negative. Autoantibodies were negative, including anti-mitochondrial, smooth muscle, antinuclear, and perinuclear anti-neutrophil cytoplasmic antibody. Gamma globulin was within the normal limits. The hemolytic complement activity (CH50) was elevated slightly. Abdominal computed tomography showed a severely swollen gallbladder, normal intra- and extrahepatic bile ducts, and normal liver shape and architecture (Figure 1, top). Magnetic resonance imaging showed an edematous,
thickened gallbladder wall, perportal edema, slight ascites, and a normal liver, bile duct, and pancreatic duct (Figure 1, bottom). Based on these findings, the patient was diagnosed with severe acute cholestatic hepatitis of unknown etiology. The total bilirubin level continued to rise, and so the patient was started on predonine 20 mg daily on 7 May 2008. The serum aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase levels normalized gradually, while the total bilirubin remained high. Oral Inchinko-to at 7.5 g daily was prescribed on 17 May 2008. He was weaned from predonine. Subsequently, the total bilirubin level began to decrease (Figure 2). A liver biopsy showed chronic active hepatitis with mild fibrosis (A2, F1).

The patient was discharged. He is currently well at 12 mo after UDCA and Inchinko-to treatment.

**DISCUSSION**

Without evidence of a virus infection, autoimmune disease, alcohol or drug use, blood or blood products administration, and environmental hazards, the patient was considered to have severe acute cholestatic hepatitis of unknown etiology. Initially, predonine was prescribed for suspected autoimmune hepatitis with a high total bilirubin level. The increasing total bilirubin was thought to suggest progression to subacute fulminant hepatitis. Inchinko-to, a Chinese herbal medicine, has been used clinically for various liver diseases in Japan and China.

Recent experimental studies have clarified the molecular mechanism of hepatoprotective and choleretic effects of Inchinko-to and its ingredients, and have provided a good rationale for its clinical application to a wide variety of liver diseases, although there is no sound evidence with prospective randomized clinical studies. The ingredients of Inchinko-to are genipin, 6,7-dimethylesculetin, capillin, capillene, and capillarisin. Therefore, we decided to give Inchinko-to to our patient who suffered from severe acute cholestatic hepatitis of unknown etiology. The treatment was effective with no adverse effects.

The death of liver cells in hepatitis is thought to involve apoptosis. Fas/FasL-mediated cytotoxicity is critical to hepatic injury, particularly fulminant hepatitis. Genipin markedly suppressed liver apoptosis/injury in a lethal fulminant hepatitis model and improved acute liver dysfunction by the suppression of tumor necrosis factor-α production. In addition, capillin and capillene inhibit liver cell apoptosis induced by transforming growth factor-β. Cholestasis results in hepatic and systemic accumulation of potentially toxic bile acids, resulting in liver damage and jaundice. The altered expression of specific hepatocellular transport systems and profound changes in the cytoskeleton of the hepatocytes are associated with cholestatic liver disease. In particular, the impairment of canalicular transport systems has a major role in the pathogenesis of acquired forms of intrahepatic cholestasis. Inchinko-to exerts potent choleretic effects via a bile-acid-independent mechanism of multidrug-resistance-associated protein 2 mediation and glutathione content modulation by genipin, and of constitutive...
androstane receptor activation by 6,7-dimethylesculetin. The marked reduction in bilirubin level after Inchinko-to administration in our case suggested that Inchinko-to and its ingredients stimulated and restored the impaired canalicul transport systems.

UDCA was also used in this case and it has been reported to be effective in cases of chronic liver disease and prolonged cholestasis of acute hepatitis. The therapeutic benefit of UDCA in the treatment of cholestasis may result from a combination of cytoprotective, antiapoptotic, immunomodulatory, and choleretic effects. The choleretic effects of UDCA are mediated by up-regulation of canalicul transporter protein levels, and inhibit apoptosis by modulating mitochondrial function. No apparent effect was observed on liver function tests in our case soon after the administration of UDCA. Therefore, the combination of Inchinko-to and UDCA possibly worked synergistically in improving the acute cholestatic hepatitis in this case.

Finally, our success in treating a patient with acute cholestatic hepatitis of unknown etiology supports a previous study, and suggests its efficacy in treating such liver disease. Our findings warrant a further clinical trial.

ACKNOWLEDGMENTS

We thank Associate Professor Hitoshi Takagi, Gunma University Graduate School of Medicine and Assistant Director Yoichi Kon, Gunma Cancer Center, Ota, Gunma, Japan, for helpful advice regarding the diagnosis and treatment.

REFERENCES

1 Fujii K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 2008; 38: 646-657
2 Aburada M, Sasaki H, Harada M. Pharmacological studies of Gardeniae Fructus II. Contribution of the constituent crude drugs to choleretic activity of "Inchiko-to" in rats. Yakugaku Zasshi 1976; 96: 147-153
3 Kobayashi H, Horikoshi K, Yamatake A, Lane GJ, Yamamoto M, Miyano T. Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients. Pediatr Surg Int 2001; 17: 386-389
4 Inuma Y, Kubota M, Yagi M, Kanada S, Yamazaki M, Kinoshita Y. Effects of the herbal medicine Inchin-ko-to on liver function in postoperative patients with biliary atresia--a pilot study. J Pediatr Surg 2003; 38: 1607-1611
5 Kaiho T, Tsuichi S, Yanagisawa S, Takeuchi O, Togawa A, Okamoto R, Saigusa N, Miyazaki M. Effect of the herbal medicine Inchin-Ko-To for serum bilirubin in hepatotomized patients. Hepatogastroenterology 2008; 55: 150-154
6 Arai M, Yokosuka O, Fukai K, Kanda T, Kojima H, Kawai S, Imazeki F, Hirasa S, Ishii T, Abe T, Suda T, Saito S. A case of severe acute hepatitis of unknown etiology treated with the Chinese herbal medicine Inchin-ko-to. Hepatol Res 2004; 28: 161-165
7 Tang CP, Shiu AT, Huang YH, Tsay SH, Hsu TI, Wu JC, Lin HC, Lee SD. Cholestatic jaundice as the predominant presentation in a patient with autoimmune hepatitis. J Chin Med Assoc 2008; 71: 45-48
8 Yamamoto M, Ogawa K, Morita M, Fukuda K, Komatsu Y. The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1. Hepatol 1996; 23: 552-559
9 Yamamoto M, Miura N, Ohtake N, Amagaya S, Ishige A, Sasaki H, Komatsu Y, Fukuda K, Ito T, Terasawa K, Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice. Gastroenterology 2000; 118: 380-389
10 Takeuchi S, Tato T, Mikami K, Miura K, Ohshima S, Yoneyama K, Sato M, Shibuya T, Watanabe D, Kataoka E, Segawa D, Endo A, Sato W, Yoshino R, Watanabe S. Genipin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of TNF-alpha production. Hepatol Res 2005; 33: 298-305
11 Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, Suzuki H, Sugiyama Y. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatol 2004; 39: 167-178
12 Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004; 113: 137-143
13 Okada K, Shoda J, Kano M, Suzuki S, Ohtake N, Yamamoto M, Takahashi H, Utsunomiya H, Oda K, Sato K, Watanabe A, Ishii T, Itoh K, Yamamoto M, Yokoi T, Yoshizato K, Sugiyama Y, Suzuki H. Inchinko-to, a herbal medicine, and its ingredients dually exert Mrp2/Mrp2-mediated cholestasis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1450-G1463
14 Takeda S, Yuasa K, Endo T, Aprurada M. Pharmacological studies on iridoid compounds. II. Relationship between structures and choleretic actions of iridoid compound. J Pharmacobiodyn 1980; 3: 485-492
15 Sakagami Y, Mizoguchi Y, Seki S, Miyajima K, Kobayashi K, Shin T, Takeda H, Morisawa S. Effect of Inchin-ko-to treatment on intrahepatic cholestasis and acute severe hepatitis [English abstract]. J Med Pharm Soc Wakan-Yaku 1987; 4: 124-129
16 Kondo T, Suda T, Fukuyama Y, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-413
17 Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzaawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809
18 Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-1227
19 Takano S, Ito Y, Yokosuka O, Ohno M, Uchiimi K, Hirota K, Omata M. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 358-364
20 Kadayiﬁc A, Savas MC, Arslan S, Gullu H. Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. J Clin Gastroenterol 1997; 24: 125-126
21 Beuers U, Boyer JL, Palumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998; 28: 1449-1453
22 Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk Fickert P. Essential roles of the Fas ligand in the development of hepatitis [English abstract]. J Med Pharm Soc Wakan-Yaku 1987; 4: 124-129
23 Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790-2799